baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Qiagen NV/ NL0015001WM6 /

20/05/2024 21:59:44	Chg. -0.23	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
45.47USD	-0.50%	35,721 Turnover: 1.62 mill.	-Bid Size: -	-Ask Size: -	10.43 bill.USD	-	30.47

GlobeNewswire 14/05 QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical devic...

GlobeNewswire 13/05 QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accura...

GlobeNewswire 07/05 QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics

GlobeNewswire 02/05 QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inher...

GlobeNewswire 29/04 QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance

GlobeNewswire 25/04 deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ...

GlobeNewswire 24/04 QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and comba...

GlobeNewswire 18/04 deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing...

GlobeNewswire 09/04 QIAGEN N.V. to release results for Q1 2024 and hold webcast

GlobeNewswire 03/04 QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Ann...

GlobeNewswire 25/03 QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration a...

GlobeNewswire 18/03 QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosi...

GlobeNewswire 11/03 QIAGEN announces Form 20-F annual report filing for 2023 results

GlobeNewswire 27/02 QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

GlobeNewswire 27/02 QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Plati...

GlobeNewswire 15/02 QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Plati...

GlobeNewswire 06/02 QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved op...

TeleTrader 06/02 Europe higher at close, economic prints in spotlight

TeleTrader 29/01 Europe opens mixed ahead of data

GlobeNewswire 25/01 QIAGEN announces partnership with Penn State University to advance microbiome sciences

GlobeNewswire 18/01 QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 mi...

GlobeNewswire 11/01 QIAGEN N.V. to release results for Q4 2023 and hold webcast

GlobeNewswire 08/01 QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Sy...

GlobeNewswire 07/01 QIAGEN announces plans to return approximately $300 million to shareholders

GlobeNewswire 04/01 QIAGEN to accelerate investments into QIAGEN Digital Insights bioinformatics business

Qiagen NV/ NL0015001WM6 /

If you wish to receive reply to your feedback, please provide your email address.